Stefanie Dedeurwaerdere

List of Publications by Year
in descending order

57 papers	1,905 citations	218677 26 h-index	265206 42 g-index
58 all docs	58 docs citations	58 times ranked	2652 citing authors

#	Article	IF	Citations
1	What value can TSPO PET bring for epilepsy treatment?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 221-233.	6.4	11
2	TSPO PET upregulation predicts epileptic phenotype at disease onset independently from chronic TSPO expression in a rat model of temporal lobe epilepsy. NeuroImage: Clinical, 2021, 31, 102701.	2.7	9
3	Neuroimaging of Subacute Brain Inflammation and Microstructural Changes Predicts Long-Term Functional Outcome after Experimental Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 768-788.	3.4	32
4	Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acidâ€“induced temporal lobe epilepsy in rats. Epilepsia Open, 2019, 4, 92-101.	2.4	1
5	Hypersynchronicity in the default mode-like network in a neurodevelopmental animal model with relevance for schizophrenia. Behavioural Brain Research, 2019, 364, 303-316.	2.2	11
6	In vivo measurement of brain network connectivity reflects progression and intrinsic disease severity in a model of temporal lobe epilepsy. Neurobiology of Disease, 2019, 127, 45-52.	4.4	19
7	Non-invasive PET imaging of brain inflammation at disease onset predicts spontaneous recurrent seizures and reflects comorbidities. Brain, Behavior, and Immunity, 2017, 61, 69-79.	4.1	30
8	Decreased levels of active <scp>uPA</scp> and <scp>KLK</scp>8 assessed by [¹¹¹In]<scp>MICA</scp>â€401 binding correlate with the seizure burden in an animal model of temporal lobe epilepsy. Epilepsia, 2017, 58, 1615-1625.	5.1	5
9	Neuroinflammation imaging markers for epileptogenesis. Epilepsia, 2017, 58, 11-19.	5.1	41
10	Neuroimaging in animal models of epilepsy. Neuroscience, 2017, 358, 277-299.	2.3	18
11	WONOEP appraisal: Imaging biomarkers in epilepsy. Epilepsia, 2017, 58, 315-330.	5.1	26
12	In Vivo Imaging in Rodents. , 2017, , 197-215.		0
13	Kainic Acid-Induced Post-Status Epilepticus Models of Temporal Lobe Epilepsy with Diverging Seizure Phenotype and Neuropathology. Frontiers in Neurology, 2017, 8, 588.	2.4	57
14	Metabotropic glutamate receptor 2/3 density and its relation to the hippocampal neuropathology in a model of temporal lobe epilepsy in rats. Epilepsy Research, 2016, 127, 55-59.	1.6	6
15	P2X7 receptor antagonism reduces the severity of spontaneous seizures in a chronic model of temporal lobe epilepsy. Neuropharmacology, 2016, 105, 175-185.	4.1	57
16	Multiprobe molecular imaging of an NMDA receptor hypofunction rat model for glutamatergic dysfunction. Psychiatry Research - Neuroimaging, 2016, 248, 1-11.	1.8	13
17	In the grey zone between epilepsy and schizophrenia: alterations in group II metabotropic glutamate receptors. Acta Neurologica Belgica, 2015, 115, 221-232.	1.1	10
18	Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis. Neurobiology of Disease, 2015, 82, 526-539.	4.4	69

#	Article	IF	Citations
19	Synthesis and preclinical evaluation of an 18 F labeled PDE7 inhibitor for PET neuroimaging. Nuclear Medicine and Biology, 2015, 42, 975-981.	0.6	12
20	In Vivo Measurement of Hippocampal GABAA/cBZR Density with [18F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy. PLoS ONE, 2014, 9, e86722.	2.5	22
21	Hypolocomotive behaviour associated with increased microglia in a prenatal immune activation model with relevance to schizophrenia. Behavioural Brain Research, 2014, 258, 179-186.	2.2	93
22	Workshop on Neurobiology of Epilepsy appraisal: New systemic imaging technologies to study the brain in experimental models of epilepsy. Epilepsia, 2014, 55, 819-828.	5.1	13
23	Neural ECM and epilepsy. Progress in Brain Research, 2014, 214, 229-262.	1.4	43
24	The risk for behavioural deficits is determined by the maternal immune response to prenatal immune challenge in a neurodevelopmental model. Brain, Behavior, and Immunity, 2014, 42, 138-146.	4.1	114
25	Imaging brain inflammation in epilepsy. Neuroscience, 2014, 279, 238-252.	2.3	44
26	Towards a reproducible protocol for repetitive and semi-quantitative rat brain imaging with 18 F-FDG: Exemplified in a memantine pharmacological challenge. NeuroImage, 2014, 96, 276-287.	4.2	37
27	Subchronic memantine induced concurrent functional disconnectivity and altered ultra-structural tissue integrity in the rodent brain: revealed by multimodal MRI. Psychopharmacology, 2013, 227, 479-491.	3.1	18
28	Manganese-enhanced MRI reflects seizure outcome in a model for mesial temporal lobe epilepsy. NeuroImage, 2013, 68, 30-38.	4.2	29
29	Population derived principle component analysis based model for the [¹⁸F]PBR111 arterial input function in rats. , 2013, , .		0
30	Long-Term Valproate Treatment Increases Brain Neuropeptide Y Expression and Decreases Seizure Expression in a Genetic Rat Model of Absence Epilepsy. PLoS ONE, 2013, 8, e73505.	2.5	10
31	Increased brain metabolism after acute administration of the synthetic cannabinoid HU210: A small animal PET imaging study with 18F-FDG. Brain Research Bulletin, 2012, 87, 172-179.	3.0	14
32	PET imaging of brain inflammation during early epileptogenesis in a rat model of temporal lobe epilepsy. EJNMMI Research, 2012, 2, 60.	2.5	78
33	Finding a better drug for epilepsy: Antiinflammatory targets. Epilepsia, 2012, 53, 1113-1118.	5.1	44
34	Fluctuating and constant valproate administration gives equivalent seizure control in rats with genetic and acquired epilepsy. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 72-79.	2.0	9
35	Changes in hippocampal GABAA/cBZR density during limbic epileptogenesis: Relationship to cell loss and mossy fibre sprouting. Neurobiology of Disease, 2011, 41, 227-236.	4.4	19
36	Synthesis, In Vivo Occupancy, and Radiolabeling of Potent Phosphodiesterase Subtype-10 Inhibitors as Candidates for Positron Emission Tomography Imaging. Journal of Medicinal Chemistry, 2011, 54, 5820-5835.	6.4	43

#	Article	IF	Citations
37	Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Psychopharmacology, 2011, 214, 505-514.	3.1	32
38	Patterns of Brain Glucose Metabolism Induced by Phosphodiesterase 10A Inhibitors in the Mouse: A Potential Translational Biomarker. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 210-217.	2.5	25
39	Preclinical Evaluation of ¹⁸F-JNJ41510417 as a Radioligand for PET Imaging of Phosphodiesterase-10A in the Brain. Journal of Nuclear Medicine, 2010, 51, 1584-1591.	5.0	64
40	[18F]JNJ41510417 a potential PET radioligand for imaging phosphodiesterase-10A in the brain. NeuroImage, 2010, 52, S15.	4.2	0
41	In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 958-965.	6.4	22
42	A novel system allowing long-term simultaneous video-electroencephalography recording, drug infusion and blood sampling in rats. Journal of Neuroscience Methods, 2009, 179, 184-190.	2.5	10
43	Thalamic and limbic involvement in the mechanism of action of vagus nerve stimulation, a SPECT study. Seizure: the Journal of the British Epilepsy Association, 2008, 17, 699-706.	2.0	70
44	Neuronuclear Assessment of Patients With Epilepsy. Seminars in Nuclear Medicine, 2008, 38, 227-239.	4.6	133
45	Positron Emission Tomography in Basic Epilepsy Research: A View of the Epileptic Brain. Epilepsia, 2007, 48, 56-64.	5.1	23
46	Vagus nerve stimulation does not affect spatial memory in fast rats, but has both anti-convulsive and pro-convulsive effects on amygdala-kindled seizures. Neuroscience, 2006, 140, 1443-1451.	2.3	26
47	Neuromodulation with levetiracetam and vagus nerve stimulation in experimental animal models of epilepsy. Acta Neurologica Belgica, 2006, 106, 91-7.	1.1	5
48	Rapid kindling in preclinical anti-epileptic drug development: The effect of levetiracetam. Epilepsy Research, 2005, 67, 109-116.	1.6	14
49	Small animal positron emission tomography during vagus nerve stimulation in rats: A pilot study. Epilepsy Research, 2005, 67, 133-141.	1.6	38
50	Long-term Deep Brain Stimulation for Refractory Temporal Lobe Epilepsy. Epilepsia, 2005, 46, 98-99.	5.1	72
51	The Acute and Chronic Effect of Vagus Nerve Stimulation in Genetic Absence Epilepsy Rats from Strasbourg (GAERS). Epilepsia, 2005, 46, 94-97.	5.1	24
52	Generator replacement in epilepsy patients treated with vagus nerve stimulation. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 89-99.	2.0	29
53	Chronic levetiracetam treatment early in life decreases epileptiform events in young GAERS, but does not prevent the expression of spike and wave discharges during adulthood. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 403-411.	2.0	23
54	Acute vagus nerve stimulation does not suppress spike and wave discharges in â€œGenetic Absence Epilepsy Rats from Strasbourgâ€ Epilepsy Research, 2004, 59, 191-198.	1.6	25

#	Article	IF	Citations
55	Vagus Nerve Stimulation for Refractory Epilepsy: A Transatlantic Experience. Journal of Clinical Neurophysiology, 2004, 21, 283-289.	1.7	108
56	Detection of spike and wave discharges in the cortical EEG of genetic absence epilepsy rats from Strasbourg. Physics in Medicine and Biology, 2003, 48, 1685-1700.	3.0	28
57	The Mechanism of Action of Vagus Nerve Stimulation for Refractory Epilepsy. Journal of Clinical Neurophysiology, 2001, 18, 394-401.	1.7	77